Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT

被引:9
作者
Laudicella, Riccardo [1 ,2 ,3 ]
La Torre, Flavia [1 ]
Davi, Valerio [1 ]
Croce, Ludovica [1 ]
Arico, Demetrio [4 ]
Leonardi, Giuseppe [1 ]
Russo, Simona [1 ]
Minutoli, Fabio [1 ]
Burger, Irene A. [2 ,3 ]
Baldari, Sergio [1 ]
机构
[1] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Nucl Med Unit, I-98125 Messina, Italy
[2] Univ Zurich, Univ Hosp Zurich, Dept Nucl Med, CH-8091 Zurich, Switzerland
[3] Kantonsspital Baden, Dept Nucl Med, CH-5404 Baden, Switzerland
[4] Humanitas Oncol Ctr Catania, Dept Nucl Med, I-95125 Catania, Italy
关键词
prostate cancer; PET; PSMA; choline; biochemical recurrence; DIAGNOSIS;
D O I
10.3390/tomography8050205
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [Ga-68]Ga-PSMA-11 PET/CT, but positive on [F-18]Fluoromethylcholine (Choline) PET/CT.
引用
收藏
页码:2471 / 2474
页数:4
相关论文
共 20 条
[1]   Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Zechmann, Christian M. ;
Malcher, Anna ;
Eder, Matthias ;
Eisenhut, Michael ;
Linhart, Heinz G. ;
Holland-Letz, Tim ;
Hadaschik, Boris A. ;
Giesel, Frederik L. ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20
[2]   PSMA-negative prostate cancer and the continued value of choline-PET/CT [J].
Alberts, Ian ;
Sachpekidis, Christos ;
Fech, Viktor ;
Rominger, Axel ;
Afshar-Oromieh, Ali .
NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2020, 59 (01) :33-34
[3]   Brain PET/CT using prostate cancer radiopharmaceutical agents in the evaluation of gliomas [J].
Alongi, Pierpaolo ;
Quartuccio, Natale ;
Arnone, Annachiara ;
Kokomani, Aurora ;
Allocca, Michela ;
Nappi, Anna Giulia ;
Santo, Giulia ;
Mantarro, Cristina ;
Laudicella, Riccardo .
CLINICAL AND TRANSLATIONAL IMAGING, 2020, 8 (06) :433-448
[4]   Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements [J].
Baratto, Lucia ;
Duan, Heying ;
Laudicella, Riccardo ;
Toriihara, Akira ;
Hatami, Negin ;
Ferri, Valentina ;
Iagaru, Andrei .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (01) :115-122
[5]   68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes [J].
Barbaud, Matthieu ;
Frindel, Mathieu ;
Ferrer, Ludovic ;
Le Thiec, Maelle ;
Rusu, Daniela ;
Rauscher, Aurore ;
Maucherat, Bruno ;
Baumgartner, Pierre ;
Fleury, Vincent ;
Colombie, Mathilde ;
Thierry-Morel, Agnes ;
Kraeber-Bodere, Francoise ;
Campion, Loic ;
Rousseau, Caroline .
PROSTATE, 2019, 79 (05) :454-461
[6]   The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients [J].
Bauckneht, Matteo ;
Bertagna, Francesco ;
Donegani, Maria Isabella ;
Durmo, Rexhep ;
Miceli, Alberto ;
De Biasi, Vincenzo ;
Laudicella, Riccardo ;
Fornarini, Giuseppe ;
Berruti, Alfredo ;
Baldari, Sergio ;
Versari, Annibale ;
Giubbini, Raffaele ;
Sambuceti, Gianmario ;
Morbelli, Silvia ;
Albano, Domenico .
PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) :1198-1207
[7]   EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J].
Cornford, Philip ;
van den Bergh, Roderick C. N. ;
Briers, Erik ;
Van den Broeck, Thomas ;
Cumberbatch, Marcus G. ;
De Santis, Maria ;
Fanti, Stefano ;
Fossati, Nicola ;
Gandaglia, Giorgio ;
Gillessen, Silke ;
Grivas, Nikolaos ;
Grummet, Jeremy ;
Henry, Ann M. ;
van der Kwast, Theodorus H. ;
Lam, Thomas B. ;
Lardas, Michael ;
Liew, Matthew ;
Mason, Malcolm D. ;
Moris, Lisa ;
Oprea-Lager, Daniela E. ;
van der Poel, Henk G. ;
Rouviere, Olivier ;
Schoots, Ivo G. ;
Tilki, Derya ;
Wiegel, Thomas ;
Willemse, Peter-Paul M. ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2021, 79 (02) :263-282
[8]   Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes [J].
Emmett, Louise ;
Metser, Ur ;
Bauman, Glenn ;
Hicks, Rodney J. ;
Weickhardt, Andrew ;
Davis, Ian D. ;
Punwani, Shonit ;
Pond, Greg ;
Chua, Sue ;
Ho, Bao ;
Johnston, Edward ;
Pouliot, Frederic ;
Scott, Andrew M. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (06) :794-800
[9]   Epidemiology and Prevention of Prostate Cancer [J].
Gandaglia, Giorgio ;
Leni, Riccardo ;
Bray, Freddie ;
Fleshner, Neil ;
Freedland, Stephen J. ;
Kibel, Adam ;
Stattin, Par ;
Van Poppel, Hendrick ;
La Vecchia, Carlo .
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (06) :877-892
[10]   High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics [J].
Kesch, Claudia ;
Yirga, Leubet ;
Dendl, Katharina ;
Handke, Analena ;
Darr, Christopher ;
Krafft, Ulrich ;
Radtke, Jan Philipp ;
Tschirdewahn, Stephan ;
Szarvas, Tibor ;
Fazli, Ladan ;
Gleave, Martin ;
Giesel, Frederik L. ;
Haberkorn, Uwe ;
Hadaschik, Boris .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 49 (01) :385-389